Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

Completed · Phase 4 · Has a placebo group

Conditions studied: Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders

In brief

Adolescents with attention deficit hyperactivity disorder (ADHD) often develop substance use disorders (SUD). The purpose of this study is to evaluate the effectiveness of atomoxetine in treating adolescents dually diagnosed with ADHD and SUD.

Key facts

Study ID

NCT00218322

Run by

Massachusetts General Hospital

People needed

108

Starts

2004-09-01

Expected to finish

2006-04-01

Last updated by the study team

2012-11-07

Who can join

Age: 15 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• DSM-IV diagnosis of ADHD
• Current or recent (within the three months prior to study entry) SUD, including marijuana and alcohol abuse
• ADHD CGI-S score of greater to or equal to 4

You may not qualify if…

• Any Unstable medical condition
• Recent history of intravenous drug use or cocaine dependence
• Currently abusing ecstasy, cocaine, gamma-hydroxybutyrate, methamphetamine, amphetamine, opioids, phencyclidine, or benzodiazepine
• Mental retardation or organic brain syndrome
• Currently psychotic or history of bipolar disorder
• Currently taking any psychotropic or anti-substance abuse disorder medications
• Current DSM-IV diagnosis of major depression, depressive disorder, or anorexia
• Pregnant or breastfeeding

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.